AIBOTICS, INC. is a U.S.-based early-stage company in the medicinal chemicals and botanical products space that is still building its operating business. Recent filings indicate minimal to no operating revenue and a cost structure dominated by general and administrative spending, including consulting, legal/professional fees, board compensation, and product development. The company’s near-term focus appears to be advancing product development and funding operations, with management disclosing substantial doubt about its ability to continue as a going concern. The balance sheet includes intangible assets (intellectual property) that are amortized and subject to impairment testing, making execution and financing outcomes central to the equity story.
−84 501,7 %
100,0 %
−101 500,3 %
0.06
0.06
| % | |
|---|---|
| Product development (medicinal chemicals/botanicals) | 70% R&D and development activities intended to create commercial medicinal or botanical products. |
| Intellectual property (IP) assets | 20% Acquired or developed IP recorded as finite-lived intangibles that may support future commercialization or licensing. |
| Other/early commercialization activities | 10% Early-stage sales efforts, marketing, and initial customer/partner engagement ahead of meaningful revenue. |
The company has not disclosed a stable commercial customer base in the provided excerpts and reported little to no...
Would buy medicinal chemical or botanical products/ingredients for incorporation into finished goods; adoption depends on efficacy, quality, and regulatory fit.
May license or co-develop IP to accelerate commercialization and reduce funding burden for development and market entry.
Small initial customers used to validate product-market fit and generate reference use cases prior to broader rollout.
The company is domiciled in the United States, but the provided excerpts do not disclose a revenue-by-geography split...
Management’s disclosed strategy is dominated by sustaining operations while developing the business, with substantial...
Working capital deficits and recurring losses make external funding central to continued operations.
Minimal revenue indicates the business must translate development into sellable products or licensable IP.
The most acute company-specific risk is liquidity: management has disclosed substantial doubt about the company’s...
Management disclosed recurring losses, negative operating cash flows, and significant working capital deficits, implying reliance on new financing.
The company states it is devoting substantially all efforts to developing the business and raising capital with no assurance of success.
Motors & Generators
AIXN · Retail-Drug Stores and Proprietary Stores
BIXT · Pharmaceutical Preparations
CHUC · Medicinal Chemicals & Botanical Products
BIOF · Industrial Organic Chemicals
PKTX · Pharmaceutical Preparations
: 11/08/2026